

## INTRODUCTION

The emergence of infectious diseases caused by new pathogens or multidrug-resistant (MDR) strains has been a global health threat over the last decades.<sup>1</sup> These infections are among the most severe healthcare problems and have been associated to several deaths and heavy economic burden per year.<sup>2,3</sup> The imidazole ring is present in several natural and synthetic molecules with biological activity namely on effective antimicrobial agents, which make it a vital anchor for the development of new therapeutic molecules in this field.<sup>4</sup> Furthermore, amidrazones are known for their high reactivity, thus being useful intermediates for the synthesis of compounds with a wide range of biological activities, including antimicrobial. The amidrazones derivatives have been applied in different subjects of chemistry, specifically in the synthesis of azo molecules.<sup>5</sup>

In a previous work, novel imidazole-based 5-aminoimidazole-4-carboxamidrazones were prepared and exhibited potent antimicrobial activity against *C. krusei* and *C. albicans*.<sup>6</sup> Further biological studies to elucidate the action mechanism revealed an interesting relationship between the antimicrobial activity and total intracellular ROS production by the yeasts.<sup>7</sup> Here, we present results obtained from its electrochemical and chemical oxidation, as well the antimicrobial activity of the oxidized products.

## SYNTHESIS

Studies on the reactivity of amidrazones led us to find that the oxidation of amidrazones **1** in the presence of silver nitrate gave rise to azoimidazoles in the form of HNO<sub>3</sub> salts (**2**). The neutralization of these products generated azoimidazoles **3**.

## ELECTROCHEMICAL CHARACTERIZATION

Cyclic voltammograms (CV) were obtained from -0.3 to 0.3 V in a three-electrode cell using an Autolab PGSTAT 30 (Eco-Chemie) controlled by GPES 4.9 software. The working electrode was a glassy carbon electrode, a Pt wire and an Ag/AgCl (KCl 1M) were used as counter and reference electrode, respectively. Tetrabutylammonium tetrafluoroborate (TBAB) was used as supporting electrolyte.




Figure 1 – CV obtained from 2.00 mM of **1** in acetonitrile containing TBAB (0.1 M) using a glassy carbon working electrode, at different scan rates 20-400 mV/s.

Table 1 – Anodic (Epa) and cathodic (Epc) peak potential, peak separation (ΔEp), anodic peak potential minus half-wave potential (Epa-E<sub>1/2</sub>) and anodic and cathodic peak current ratios (Ipa/Ipc). Values obtained from CV at 100 mV/s scan rate.

Epa (mV)	-Epc (mV)	ΔEp (mV)	Epa-E <sub>1/2</sub> (mV)	Ipa/Ipc
13	69	82	63	0.92

Effect of scan rate (v) on potential and current

- Epa and Epc do not shift with the increase of v.
- ΔEp and Epa-E<sub>1/2</sub> values are consistent with a reversible one-electron process.
- Ipa/Ipc are always approximately 1.
- Direct proportionality between Ipa and Ipc with v.

All diagnostic criteria indicate a reversible one-electron process.<sup>8</sup>

## ANTIMICROBIAL TESTS

The antifungal activity of the azoimidazoles in the form of HNO<sub>3</sub> salts (**2**) was evaluated against yeasts (*Candida* and *Cryptococcus* strains) and against filamentous fungi (*Aspergillus*, *Fusarium*, *Scedosporium*, *Mucor* and dermatophyte strains). The antibacterial activity of these compounds was also evaluated against Gram-negative (*Escherichia coli*) and Gram-positive (*Staphylococcus aureus*) bacteria.

Table 2 – Antifungal activity (MIC and MLC) of the azoimidazoles **2** against yeasts (*Candida* and *Cryptococcus* strains).

		<i>Candida albicans</i> ATCC 10231	<i>Candida albicans</i> DSY294 (S)	<i>Candida albicans</i> DSY296 (R)	<i>Candida glabrata</i> DSY562 (S)	<i>Candida glabrata</i> DSY565 (R)	<i>Candida krusei</i> ATCC 6258	<i>Cryptococcus neoformans</i> CECT1078
MIC <sup>a</sup>	<b>2a</b>	64 (128)	32 (128)	16 (128)	64 (128)	64 (128)	4 (4)	2 (4)
(MLC <sup>b</sup> ) μg/mL	<b>2b</b>	64 (256)	32 (256)	32 (256)	64 (256)	64 (256)	4 (4)	4 (4)

Table 3 – Antifungal activity (MIC and MLC) of the azoimidazoles **2** against filamentous fungi: *Aspergillus*, *Fusarium*, *Scedosporium*, *Mucor* and dermatophyte strains.

		<i>Aspergillus fumigatus</i> ATCC 204305	<i>Aspergillus niger</i> ATCC 16404	<i>Fusarium solani</i> FF125	<i>Scedosporium</i> spp.	<i>Mucor</i> spp.	<i>Trichophyton rubrum</i> FF5	<i>Trichophyton mentagrophytes</i> FF7	<i>Nannizzia gypsea</i> FF3
MIC <sup>a</sup>	<b>2a</b>	256 (>256)	256 (>256)	256 (>256)	256 (256)	>256 (>256)	64 (128)	64 (64)	128 (256)
(MLC <sup>b</sup> ) μg/mL	<b>2b</b>	256 (>256)	256 (>256)	256 (>256)	256 (>256)	256 (>256)	64 (128)	32 (64)	128 (≥256)


Table 4 – Antibacterial activity (MIC and MLC) of the azoimidazoles **2** against Gram-negative (*Escherichia coli*) and Gram-positive (*Staphylococcus aureus*) bacteria.

		<i>Escherichia coli</i> ATCC 25922	<i>Staphylococcus aureus</i> ATCC 25923
MIC <sup>a</sup>	<b>2a</b>	>256 (>256)	128 (>256)
(MLC <sup>b</sup> ) μg/mL	<b>2b</b>	>256 (>256)	64 (≥256)

a) MIC-minimum inhibitory concentration; b) MLC-minimum lethal concentration.  
(S) - Fluconazole susceptible strain; (R) - Fluconazole resistant strain

## CONCLUSIONS

- Amidrazones **1** were easily oxidized with silver nitrate to give azoimidazoles **3** in excellent - very good yields.
- Cyclic voltammogram of **1** obtained in the -0.3 to 0.3 V potential range showed a reversible peak involving an electron at an extremely low oxidation potential, which proves the susceptibility of **1** to oxidation reactions.
- Azoimidazoles **2** exhibited good—moderate activity against *Candida*, *Cryptococcus* and dermatophyte strains.
- On the contrary, activity against other filamentous fungi and bacteria decreased significantly.



Scheme 1 – Synthesis of azoimidazoles **3** from the oxidation of 5-aminoimidazole-4-carboxamidrazones **1**

**Acknowledgements:** We thank Fundação para a Ciência e a Tecnologia (FCT) for financial support through the Chemistry Research Centre of the University of Minho (UID/QUI/00686/2020) and CIIMAR (UIDB/04423/2020). This work was also supported under the projects MEDCOR (PTDC/CTM-TEX/1213/2020) and UID/CTM/00264/2019, and the PhD grant SFRH/BD/137668/2018.

### References:

- Morsy M. A.; Ali E. M.; Kandeel M.; Venugopala K. N.; Nair A. B.; Greish K.; El-Daly M. *Antibiotics* **2020**, *9* (5).
- van Oosterhout C.; Hall N.; Ly H.; Tyler K. M. *Virulence* **2021**, *12* (1), 507-508.
- Pietsch F.; O'Neill A. J.; Ivask A.; Jenssen H.; Inkinen J.; Kahru A.; Ahonen M.; Schreiber F. *Journal of Hospital Infection* **2020**, *106* (1), 115-125.
- Chopra P. N.; Sahu J. K. *Current Drug Discovery Technologies* **2020**, *17* (5), 574-584.
- Mazur L.; Sączewski J.; Jarzemska K. N.; Szwarc-Karabyka K.; Paprocka R.; Modzelewska-Banachiewicz B. *Cryst Eng Comm* **2018**, *20* (29), 4179-4193.
- Ribeiro A. I.; Gabriel C.; Cerqueira F.; Maia M.; Pinto E.; Sousa J. C.; Medeiros R.; Proença M. F.; Dias A. M. *Bioorganic & Medicinal Chemistry Letters* **2014**, *24* (19), 4699-4702.
- Cerqueira F.; Maia M.; Gabriel C.; Medeiros R.; Cravo S.; Ribeiro A. I.; Dantas D.; Dias A. M.; Saraiva L.; Raimundo L.; Pinto E. *Antibiotics* **2021**, *10* (2).
- Brett C. M. A.; Brett A. M. O. *Electrochemistry: Principles, Methods, and Applications*; Oxford University Press: Oxford; New York, 1993.